tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksMost Visited WebsitesDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by Upside
New
Top ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
New
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock ScreenerETF Screener
Popular
Trending StocksDaily Analyst RatingsCompare StocksCompare ETFsPenny Stock ScreenerTechnical Analysis ScreenerDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Personal Finance CenterMortgagesLoansInvesting & RetirementSpending & Savings
Calculators
401k Retirement CalculatorMortgage Calculator
Popular
Compound Interest CalculatorDollar Cost Averaging
New
Student Loan CalculatorAuto Loan Calculator
Education
How To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsTop Online BrokersBecome an Affiliate
Follow Us
NewsTrendingPortfolio
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Top ETFs
Top Smart Score Stocks
Popular
Earnings
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
Most Visited Websites
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock Screener
ETF Screener
Popular
Trending Stocks
Daily Analyst Ratings
Compare Stocks
Compare ETFs
Penny Stock Screener
Technical Analysis Screener
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
Follow Us

CLNN Stock Latest News

Clene to Present at the Emerging Growth Conference
Press ReleasesClene to Present at the Emerging Growth Conference
5d ago
CLNN
Clene Announces Plans to Submit Briefing Book to the U.S. Food and Drug Administration in Connection with Granted Type C Interaction to Obtain FDA Feedback on Potential Pathway to Accelerated Approval for CNM-Au8® in ALS
PremiumPress Releases
Clene Announces Plans to Submit Briefing Book to the U.S. Food and Drug Administration in Connection with Granted Type C Interaction to Obtain FDA Feedback on Potential Pathway to Accelerated Approval for CNM-Au8® in ALS
6d ago
CLNN
Clene announces plans to submit briefing book to U.S. FDA
PremiumThe Fly
Clene announces plans to submit briefing book to U.S. FDA
6d ago
CLNN
Clene trading halted, news pending
PremiumThe Fly
Clene trading halted, news pending
7d ago
CLNN
Clene Announces Reverse Stock Split and Share Structure Changes
PremiumCompany Announcements
Clene Announces Reverse Stock Split and Share Structure Changes
9d ago
8K
CLNN
Clene Announces 1-for-20 Reverse Stock Split
PremiumPress ReleasesClene Announces 1-for-20 Reverse Stock Split
9d ago
CLNN
Clene announces 1-for-20 reverse stock split
PremiumThe Fly
Clene announces 1-for-20 reverse stock split
9d ago
CLNN
Clene to Present at H.C. Wainwright’s 5th Annual Neuro Perspectives Virtual Conference
PremiumPress Releases
Clene to Present at H.C. Wainwright’s 5th Annual Neuro Perspectives Virtual Conference
24d ago
CLNN
Clene presents preliminary data on CNM-Au8 in Rett Syndrome
PremiumThe Fly
Clene presents preliminary data on CNM-Au8 in Rett Syndrome
27d ago
CLNN
Clene Presents Preliminary Data for CNM-Au8® as a Potential Treatment for Rett Syndrome
PremiumPress Releases
Clene Presents Preliminary Data for CNM-Au8® as a Potential Treatment for Rett Syndrome
27d ago
CLNN
Clene Reveals Breakthrough ALS Trial Results and Extended Survival Data
PremiumCompany Announcements
Clene Reveals Breakthrough ALS Trial Results and Extended Survival Data
30d ago
8K
CLNN
Clene presents extended survival data on CNM-Au8 from HEALEY ALS trial
PremiumThe Fly
Clene presents extended survival data on CNM-Au8 from HEALEY ALS trial
30d ago
CLNN
Clene Presents Extended Survival Data Through 3.5 Years and New NfL Responder Results with CNM-Au8® 30 mg Treatment from the HEALEY ALS Platform Trial Open Label Extension at the 2024 ENCALS Meeting
PremiumPress ReleasesClene Presents Extended Survival Data Through 3.5 Years and New NfL Responder Results with CNM-Au8® 30 mg Treatment from the HEALEY ALS Platform Trial Open Label Extension at the 2024 ENCALS Meeting
30d ago
CLNN
Clene to Present at the Emerging Growth Conference
PremiumPress Releases
Clene to Present at the Emerging Growth Conference
1M ago
CLNN
Clene Shareholders Approve Expansion and Governance Changes
PremiumCompany Announcements
Clene Shareholders Approve Expansion and Governance Changes
2M ago
8K
CLNN
Clene provides update on expanded access program for CNM-Au8
PremiumThe Fly
Clene provides update on expanded access program for CNM-Au8
2M ago
CLNN
Clene Provides Update on Its NIH-Funded Expanded Access Program for CNM-Au8® in ALS (ACT-EAP)
PremiumPress Releases
Clene Provides Update on Its NIH-Funded Expanded Access Program for CNM-Au8® in ALS (ACT-EAP)
2M ago
CLNN
Clene to Present at Upcoming May Conferences
PremiumPress Releases
Clene to Present at Upcoming May Conferences
2M ago
CLNN
Clene sees cash, equivalents sufficient to fund operations into 4Q24
PremiumThe Fly
Clene sees cash, equivalents sufficient to fund operations into 4Q24
2M ago
CLNN
Clene reports Q1 EPS (9c), consensus (8c)
PremiumThe FlyClene reports Q1 EPS (9c), consensus (8c)
2M ago
CLNN
Clene Reports First Quarter 2024 Financial Results and Recent Operating Highlights
PremiumPress Releases
Clene Reports First Quarter 2024 Financial Results and Recent Operating Highlights
2M ago
CLNN
Is CLNN a Buy, Before Earnings?
PremiumPre-Earnings
Is CLNN a Buy, Before Earnings?
2M ago
CLNN

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >